LoginRegister
    Biocon gets 6 USFDA observations for Bengaluru plantBiocon gets 6 USFDA observations for Bengaluru plant
    Cipla to launch Cinacalcet Hydrochloride tablets, a generic version of SensiparCipla to launch Cinacalcet Hydrochloride tablets, a generic version of Sensipar
    USFDA approves Spravato, a controversial drug for depressionUSFDA approves Spravato, a controversial drug for depression
    Glenmark Pharma appoints Alessandro Riva as CEO of its new innovation companyGlenmark Pharma appoints Alessandro Riva as CEO of its new innovation company
    Setback to JnJ baby Powder: DCGI issues show cause notice for violating drug lawSetback to JnJ baby Powder: DCGI issues show cause notice for violating drug law
    Smuggling of anti cancer drug in India worth Rs 1.23 crore, Chinese arrested at airportSmuggling of anti cancer drug in India worth Rs 1.23 crore, Chinese arrested at airport
    Alembic Pharma JV Aleor gets USFDA nod for Clobetasol Propionate ointmentAlembic Pharma JV Aleor gets USFDA nod for Clobetasol Propionate ointment
    Lupin, Natco receives USFDA nod for Imatinib Mesylate tabletsLupin, Natco receives USFDA nod for Imatinib Mesylate tablets
    Zydus Cadila gets USFDA nod to Rivastigmine transdermal system, RosuvastatinZydus Cadila gets USFDA nod to Rivastigmine transdermal system, Rosuvastatin
    CHMP recommends Sanofi Zynquista for treatment of adults with type 1 diabetesCHMP recommends Sanofi Zynquista for treatment of adults with type 1 diabetes
    Setback to Meril Lifesciences MeRess100: NPPA refuses to give relief of price cap exemption for the biodegradable stentSetback to Meril Lifesciences MeRess100: NPPA refuses to give relief of price cap exemption for the...
    Zydus Cadila gets USFDA nod to Doxazosin for treating BP, enlarged prostate issuesZydus Cadila gets USFDA nod to Doxazosin for treating BP, enlarged prostate issues
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X